cardiovascular function News
-
CVRx`s BAROSTIM NEO Receives CMS NTAP Effective October 1, 2020
MINNEAPOLIS, Nov. 2, 2020 - CVRx®, developer of the world's first FDA-approved neuromodulation device to treat chronic heart failure (HF), announces that its BAROSTIM NEO™ implantable device has received the Centers for Medicare & Medicaid Services (CMS) inpatient New Technology Add-On Payment (NTAP). Additionally, CMS proposed national coverage determination (NCD) for Breakthrough ...
By CVRx
-
News release: CVRx Raises $50 Million in New Equity Financing
MINNEAPOLIS, July 7, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company with a novel technology that treats patients suffering from chronic heart failure (“HF”) and resistant hypertension, announced today that it raised $50 million to close its latest round of equity financing. Proceeds from the financing will be used to support commercialization of the BAROSTIM ...
By CVRx
-
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
-
Alfa Chemistry Offers Varieties of Marine Biomaterials for Use in Biomedicine, Cosmetics and Nutraceuticals
The US-located chemical supplier Alfa Chemistry has recently unveiled its wide range of marine biomaterials, opening new possibilities in the fields of biomedicine, cosmetics, and nutraceuticals. With an extensive collection of marine polysaccharides, oligosaccharides, bioactive peptides, marine oils, and microalgae powders, researchers and industries alike can explore the potential of marine ...
-
Bodyport Appoints Amit Rushi as Chief Commercial Officer and Phyllis Whiteley, Ph.D. as Chair of the Board of Directors
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
-
Alfa Chemistry Integrates Its Supply of Dietary Supplement Ingredients
Alfa Chemistry, a reputable global supplier of research chemicals and materials, has recently announced the integration of its dietary supplement ingredients supply. This move aims to streamline the company's operations and enhance its ability to meet the growing demand for high-quality dietary supplement ingredients. Dietary supplements have gained significant popularity in recent years, with ...
-
ELIXIR MEDICAL COMPLETES ENROLLMENT IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
MILPITAS, Calif. – February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you